XML 52 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):
Years Ended December 31,
20222021
Numerator
Consolidated net income$230,064 $1,241,201 
Less: Net income attributable to Continuing Investors Partnerships23,775 297,321 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT163,457 324,152 
Net income attributable to Royalty Pharma plc - basic and diluted$42,832 $619,728 
Denominator
Weighted average Class A ordinary shares outstanding - basic437,963 414,794 
Add: Dilutive effect of unvested RSUs9 8 
Weighted average Class A ordinary shares outstanding - diluted437,972 414,802 
Earnings per Class A ordinary share - basic$0.10 $1.49 
Earnings per Class A ordinary share - diluted$0.10 $1.49 
Year Ended December 31,
2020
Numerator
Consolidated net income$1,701,954 
Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT409,921 
Net income attributable to Royalty Pharma plc - basic and diluted$495,198 
Denominator
Weighted average Class A ordinary shares outstanding - basic375,444 
Add: Dilutive effect of unvested RSUs11 
Weighted average Class A ordinary shares outstanding - diluted375,455 
Earnings per Class A ordinary share - basic$1.32 
Earnings per Class A ordinary share - diluted$1.32 
(1)Reflected as Net income attributable to Royalty Pharma plc on the consolidated statements of operations.